LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Pharmaceuticals Incorporated (the Company) was held on May 25,
2017 (the Annual Meeting). Set forth below are the final voting
results for the actions taken by the stockholders at the Annual
Meeting.
board of directors for terms expiring at the 2018 annual meeting
of stockholders. In accordance with the results below, each
nominee was elected to serve as a director.
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
||||
|
John W. Kozarich
|
16,150,486
|
559,782
|
2,634,453
|
|||
|
John L. Higgins
|
16,327,601
|
382,667
|
2,634,453
|
|||
|
Jason M. Aryeh
|
15,524,595
|
1,185,673
|
2,634,453
|
|||
|
Todd C. Davis
|
16,271,507
|
438,761
|
2,634,453
|
|||
|
John L. LaMattina
|
16,292,695
|
417,573
|
2,634,453
|
|||
|
Sunil Patel
|
15,760,838
|
949,430
|
2,634,453
|
|||
|
Stephen L. Sabba
|
15,726,666
|
983,602
|
2,634,453
|
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December 31, 2017. In accordance with
the results below, the selection of Ernst Young LLP was ratified.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
19,154,149
|
99,272
|
91,300
|
N/A
|
regarding the compensation of the Companys named executive
officers. In accordance with the results below, the resolution
was approved.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
16,257,690
|
353,761
|
98,817
|
2,634,453
|
regarding the frequency of the advisory vote on the compensation
of the Companys named executive officers. Based on the results
below, the Company has determined it will hold a stockholder
advisory vote on the compensation of the Companys named executive
officers every year.
|
Every One Year
|
Every Two Years
|
Every Three Years
|
Abstentions
|
Broker Non-Votes
|
||||
|
15,334,078
|
24,342
|
1,263,076
|
88,772
|
2,634,453
|
About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus. LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Recent Trading Information
LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) closed its last trading session down -3.31 at 110.19 with 161,405 shares trading hands.